Cell BioEngines to Present at the 2024 BIO CEO & Investor Conference NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a biotechnology company focused on the development of ‘off-the-shelf’ ‘non-gene modified’ hematopoietic stem cells and its derived...

SOSV-backed Biotech Firm Cell BioEngines Decides New York Is the Place to Be Cell BioEngines, Inc., founded by visionary Dr. Ajay Vishwakarma aiming to turn cancer into a curable disease announced today that the SOSV-backed company

Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood...

Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology BOSTON and NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc. is strengthening its Intellectual Property portfolio with a patent licensed from the Icahn School of Medicine at Mount...

Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors,...